|
 |
|
Quanta BioDesign is a research and manufacturing company committed to the development of a full range of
discrete polyethylene glycol (dPEG™) pegylation reagents for applications in diagnostics, therapeutics, peptide synthesis,
oligonucleotide synthesis, and nanotechnology. Our linear monodisperse pegylation reagents currently have MW’s from 200 D to
almost 1,300 D. These pegylation compounds have broad functional use in drug development and drug modification, as
crosslinker species for conjugation applications, especially with antibodies and in antibody production, and modification of
peptides and oligonucleotides. For biotin-labeling applications, we also offer several water-soluble biotin compounds with
various length dPEG™ linkers attached. Our customers have found our water-soluble biotin compounds to be superior to
traditional biotin-labeling compounds in nearly all applications. Our dPEG™ technology addresses numerous drug
development issues including water solubility, immunogenicity, antigenicity, aggregation, and toxicity.
The range and discreteness of our dPEG™s provides you, the customer, the option of finding just the right compound for your application.
You control the physical size and spacer or linker distance of your product based on a single compound dPEG™ of known length instead of
on a range of lengths as found with polydisperse PEGs. For further explanation of our dPEG™ technology, please click on our
Frequently Asked Questions link.
Quanta BioDesign’s vision incorporates a dedicated commitment to producing the most useful compounds for your current and future
applications and needs using synthetic and process technology that allows the most economic incorporation of these products into your application.
| | |
 |
|
